A Phase 1/2 interventional study of Golvatinib and Lenvatinib in Advanced Solid Tumors, sponsored by Eisai Inc.. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-08.
Sponsored by Eisai Inc. · Phase 1/2, Interventional, and Treatment
How we know · 5 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a multicenter, open-label, Phase 1b/2 study which will be conducted in two parts: a Phase 1b part comprising a dose escalation and an expansion cohort; and a Phase 2 part which will comprise two cohorts. The purpose of the Phase 1b part is to identify the maximum tolerated dose (MTD) of E7050 and E7080 (lenvatinib) in combination in participants with unresectable advanced or metastatic solid tumors. In the subsequent Phase 1b expansion cohort and Phase 2 cohorts, additional participants with recurrent glioblastoma or unresectable Stage III or Stage IV melanoma and disease progression after prior systemic treatment will be enrolled to confirm the MTD (expansion cohort) and to further explore the clinical activity of E7050 and lenvatinib.
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must meet all of the following criteria to be included in this study:
Phase 1b expansion cohort and Phase 2: Histological confirmed diagnosis of glioblastoma (expansion cohort and Cohort 1) or melanoma (expansion cohort and Cohort 2).
Phase 1b expansion cohort glioblastoma participants, Phase 2 Cohort 1:
defined as bidimensionally contrast enhancing lesions with clearly defined margins by computerized tomography (CT) or MRI scan, with a minimal diameter of 1 cm, and visible on two axial slices which are preferably at most 5 millimeter (mm) apart with 0 mm skip.
Phase 1b expansion cohort melanoma participants, Phase 2 Cohort 2:
Measurable disease meeting the following criteria:
All participants:
Adequate bone marrow function:
Adequate liver function:
Exclusion Criteria:
Participants who meet any of the following criteria will be excluded from this study:
Phase 2: Active (except for glioblastoma (Cohort 1) or unresectable Stage III or Stage IV melanoma (Cohort 2); or melanoma in situ, basal or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix) within the past 24 months.
Phase 1b expansion cohort glioblastoma participants and Phase 2 Cohort 1:
Participants who have received enzyme-inducing anti epileptic agents within 14 days before the first dose of study drug (e.g., carbamazepine, phenytoin, phenobarbital, primidone, or oxcarbazepine).
Phase 1b expansion cohort participants with melanoma and Phase 2 Cohort 2:
More than two prior systemic regimens for unresectable Stage III or Stage IV disease.
All participants
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with unresectable advanced or metastatic solid tumors will receive E7050 in combination with lenvatinib to identify a Maximum Tolerated Dose. Dose escalation will begin at low doses of both E7050 and lenvatinib, and then gradually increase in future cohorts until a recommended combination dose is identified. A dose of E7050 and lenvatinib to be used in combination in Phase 2 will be recommended (RP2 dose). Participants will continue on treatment until disease progression, development of unacceptable toxicity, or withdrawal of consent.
Drug: Golvatinib · Drug: Lenvatinib
Participants with recurrent glioblastoma (bevacizumab-naïve) will receive E7050 and lenvatinib at the RP2 dose.
Drug: Golvatinib · Drug: Lenvatinib
Participants with recurrent glioblastoma (bevacizumab-naïve) will receive single agent lenvatinib 24 mg/day (1\*4 mg capsule + 2\*10 mg capsule) and at time of progression, E7050 add-on therapy at the RP2 dose (in combination with lenvatinib at dose of either the RP2 dose or the most recent dose of single agent lenvatinib, whichever is the lowest).
Drug: Golvatinib · Drug: Lenvatinib
Participants with unresectable Stage III or Stage IV melanoma and disease progression after prior systemic treatment will receive E7050 and lenvatinib at the RP2 dose.
Drug: Golvatinib · Drug: Lenvatinib
Participants with unresectable Stage III or Stage IV melanoma and disease progression after prior systemic treatment will receive single agent E7050 400 mg/day.
Drug: Golvatinib
Participants will receive E7050 50 mg and/or 100 mg tablets. E7050 will be administered orally once daily, in 28-day cycles.
Also known as: E7050
Participants will receive lenvatinib 1 mg and/or 4 mg and/or 10 mg capsules. Lenvatinib will be administered orally once daily, in 28-day cycles.
Also known as: E7080
Participants will receive lenvatinib 24 mg (1\*4 mg capsule + 2\*10 mg capsule) capsules. Lenvatinib will be administered orally once daily, in 28-day cycles.
Also known as: E7080
Phase 1b: Number of Participants Who Experienced Any Dose Limiting Toxicity (DLT)- Combination Treatment
DLT was defined as toxicity related to the combination therapy and was graded according to Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0). Hematological DLTs were Grade 4 neutropenia for greater than or equal to (\>=) 7 days or Grade 3 neutropenia with fever (greater than \[\>\] 38.5 degree Celsius (°C) in axilla), Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding or lasting \>7 days and decrease of hemoglobin of Grade 4. Non-hematological DLTS were Grade 3 fatigue, or a 2 point decline in Eastern Cooperative Oncology Group (ECOG) performance status must persist for \>7days, Nausea, vomiting or diarrhea must persist at Grade 3 or 4 despite maximal medical therapy, Grade 4 hypertension or Grade 3 hypertension not able to be controlled by medication and any Grade 3 or higher non-hematological laboratory abnormalities that require hospitalization.
Time frame: Cycle 1 (Cycle length= 28 days)
Phase 1b: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Golvatinib in Combination With Lenvatinib
The MTD was defined as the highest dose level at which no more than 1/6 participants experienced a DLTs, with the next higher dose having at least 0 of 3 or 1 of 6 participants experiencing DLTs. MTD was determined by summarizing the number and percentage of participants with DLTs for the first cycle, by study dosing schedule, initial dosing level and overall for the dose escalation part. The RP2D of golvatinib in Combination with lenvatinib was MTD determined by Dose Escalation Committee (DEC) based on safety, PK and clinical data. DLT was defined as toxicity related to the combination therapy and was graded according to CTCAE v4.0.
Time frame: Cycle 1 (Cycle length= 28 days)
Phase 1b: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Lenvatinib in Combination With Golvatinib
The MTD was defined as the highest dose level at which no more than 1/6 participants experienced a DLTs, with the next higher dose having at least 0 of 3 or 1 of 6 participants experiencing DLTs. MTD was determined by summarizing the number and percentage of participants with DLTs for the first cycle, by study dosing schedule, initial dosing level and overall for the dose escalation part. The RP2D of lenvatinib in Combination with golvatinib was MTD determined by DEC based on safety, PK and clinical data. DLT was defined as toxicity related to the combination therapy and was graded according to CTCAE v4.0.
Time frame: Cycle 1 (Cycle length= 28 days)
Phase 1b: Number of Participants With Clinically Significant Change From Baseline in Laboratory Values- Combination Treatment
Time frame: From baseline up to approximately 5 years 5 months
Phase 1b: Number of Participants With Clinically Significant Change From Baseline in Vital Signs Values- Combination Treatment
Time frame: From baseline up to approximately 5 years 5 months
Phase 1b: Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Values- Combination Treatment
Time frame: From baseline up to approximately 5 years 5 months
Phase 1b: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)- Combination Treatment
Time frame: From baseline up to approximately up to 5 years 5 months
Phase 1b: Cmax; Maximum Observed Plasma Concentration for Golvatinib When Administered as a Single Agent at Day -7
Time frame: Day -7: 0-24 hours post-dose
Phase 1b: Cmax; Maximum Observed Plasma Concentration for Lenvatinib When Administered as a Single Agent at Day -8
Time frame: Day -8: 0-24 hours post-dose
Phase 1b: Tmax; Time to Reach the Maximum Plasma Concentration (Cmax) for Golvatinib When Administered as a Single Agent at Day -7
Time frame: Day -7: 0-24 hours post-dose
Phase 1b: Tmax; Time to Reach the Maximum Plasma Concentration (Cmax) for Lenvatinib When Administered as a Single Agent at Day -8
Time frame: Day -8: 0-24 hours post-dose
Phase 1b: AUC24; Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for Golvatinib When Administered as Single Agent at Day -7
Time frame: Day -7: 0-24 hours post-dose
Phase 1b: AUC24; Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for Lenvatinib When Administered as Single Agent at Day -8
Time frame: Day -8: 0-24 hours post-dose
Phase 1b: AUCt; Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for Golvatinib When Administered as Single Agent at Day -7
Time frame: Day -7: 0-24 hours post-dose
Phase 1b: AUCt; Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for Lenvatinib When Administered as Single Agent at Day -8
Time frame: Day -8: 0-24 hours post-dose
Phase 1b: AUC∞; Area Under the Plasma Concentration-time Curve From Time 0 to Infinity Calculated Using the Observed Value for the Last Quantifiable Concentration for Golvatinib When Administered as Single Agent at Day -7
Time frame: Day -7: 0-24 hours post-dose
Phase 1b: AUC∞; Area Under the Plasma Concentration-time Curve From Time 0 to Infinity Calculated Using the Observed Value for the Last Quantifiable Concentration for Lenvatinib When Administered as Single Agent at Day -8
Time frame: Day -8: 0-24 hours post-dose
Phase 1b: t1/2; Terminal Elimination Half-life for Golvatinib When Administered as Single Agent at Day -7
Time frame: Day-7: 0-24 hours post-dose
Phase 1b: t1/2; Terminal Elimination Half-life for Lenvatinib When Administered as Single Agent at Day -8
Time frame: Day -8: 0-24 hours post-dose
Phase 1b: CL/F; Apparent Clearance After Extravascular Administration Calculated Using the Observed Value of the Last Quantifiable Concentration for Golvatinib When Administered as Single Agent at Day -7
Time frame: Day -7: 0-24 hours post-dose
Phase 1b: CL/F; Apparent Clearance After Extravascular Administration Calculated Using the Observed Value of the Last Quantifiable Concentration for Lenvatinib When Administered as Single Agent at Day -8
Time frame: Day -8: 0-24 hours post-dose
Phase 1b: Vz/F; Apparent Volume of Distribution at Terminal Phase for Golvatinib When Administered as Single Agent at Day -7
Time frame: Day -7: 0-24 hours post-dose
Phase 1b: Vz/F; Apparent Volume of Distribution at Terminal Phase for Lenvatinib When Administered as Single Agent at Day -8
Time frame: Day -8: 0-24 hours post dose
Phase 1b: Cmax; Maximum Observed Plasma Concentration for Golvatinib and Lenvatinib When Administered in Combination Treatment as Single Dose on Day 1 Cycle 1
Time frame: Cycle 1 Day 1: 0-24 hours post-dose (cycle length is 28 days)
Phase 1b: Cmax; Maximum Observed Plasma Concentration for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2
Time frame: Cycle 2 Day 1: 0-24 hours post-dose (cycle length is 28 days)
Phase 1b: Tmax; Time to Reach the Maximum Plasma Concentration (Cmax) for Golvatinib and Lenvatinib When Administered in Combination Treatment as Single Dose on Day 1 Cycle 1
Time frame: Cycle 1 Day 1: 0-24 hours post-dose (cycle length is 28 days)
Phase 1b: Tmax; Time to Reach the Maximum Plasma Concentration (Cmax) for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2
Time frame: Cycle 2 Day 1: 0-24 hours post-dose (cycle length is 28 days)
Phase 1b: AUC24; Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for Golvatinib and Lenvatinib When Administered in Combination Treatment as Single Dose on Day 1 Cycle 1
Time frame: Cycle 1 Day 1: 0-24 hours post-dose (cycle length is 28 days)
Phase 1b: AUC24; Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2
Time frame: Cycle 2 Day 1: 0-24 hours post-dose (cycle length is 28 days)
Phase 1b: AUCt; Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for Golvatinib and Lenvatinib When Administered in Combination Treatment as Single Dose on Day 1 Cycle 1
Time frame: Cycle 1 Day 1: 0-24 hours post-dose (cycle length is 28 days)
Phase 1b: AUCt; Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2
Time frame: Cycle 2 Day 1: 0-24 hours post-dose (cycle length is 28 days)
Phase 1b: CLss/F; Apparent Clearance After Extravascular Administration Calculated Using the Observed Value of the Last Quantifiable Concentration for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2
Time frame: Cycle 2 Day 1: 0-24 hours post-dose (cycle length is 28 days)
Phase 1b: Rac(AUC); Accumulation Ratio Based on AUC Calculated as AUC24 at Steady State/AUC24 for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2
Time frame: Cycle 2 Day 1: 0-24 hours post-dose (cycle length is 28 days)
Phase 1b: Rac(Cmax); Accumulation Ratio Based on Cmax Calculated as Cmax at Steady State/Cmax for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2
Time frame: Cycle 2 Day 1: 0-24 hours post-dose (cycle length is 28 days)
Phase 1b: Objective Response Rate (ORR); Combination Treatment
ORR was assessed by the investigator based on Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. ORR was defined as the percentage of participants with confirmed best overall response (BOR) of complete response (CR) or partial response (PR). CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (\<)10 millimeters (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From the date of the first dose of study drug to the date of the first documentation of disease progression or death, whichever occurred first (approximately up to 5 years 5 months)
Participants took part in the study at 2 investigative sites in the United States from 13 October 2011 to 01 March 2017.
| Milestone | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Started | 5 | 3 | 14 | 8 |
| Completed | 3 | 3 | 14 | 8 |
| Not completed | 2 | 0 | 0 | 0 |
| Withdrew: Did not enter into treatment phase | 2 | 0 | 0 | 0 |
| Milestone | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Started | 3 | 3 | 14 | 8 |
| Completed | 1 | 2 | 8 | 2 |
| Not completed | 2 | 1 | 6 | 6 |
| Withdrew: Adverse event | 1 | 0 | 3 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Withdrew: Participant choice | 0 | 0 | 0 | 1 |
| Withdrew: Clinical progression | 0 | 1 | 2 | 3 |
| Withdrew: Progressive disease | 1 | 0 | 0 | 0 |
| Withdrew: Terminated by sponsor | 0 | 0 | 1 | 0 |
DLT was defined as toxicity related to the combination therapy and was graded according to Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0). Hematological DLTs were Grade 4 neutropenia for greater than or equal to (\>=) 7 days or Grade 3 neutropenia with fever (greater than \[\>\] 38.5 degree Celsius (°C) in axilla), Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding or lasting \>7 days and decrease of hemoglobin of Grade 4. Non-hematological DLTS were Grade 3 fatigue, or a 2 point decline in Eastern Cooperative Oncology Group (ECOG) performance status must persist for \>7days, Nausea, vomiting or diarrhea must persist at Grade 3 or 4 despite maximal medical therapy, Grade 4 hypertension or Grade 3 hypertension not able to be controlled by medication and any Grade 3 or higher non-hematological laboratory abnormalities that require hospitalization.
| Participants | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Phase 1b: Number of Participants Who Experienced Any Dose Limiting Toxicity (DLT)- Combination Treatment | 0 | 0 | 4 | 2 |
The MTD was defined as the highest dose level at which no more than 1/6 participants experienced a DLTs, with the next higher dose having at least 0 of 3 or 1 of 6 participants experiencing DLTs. MTD was determined by summarizing the number and percentage of participants with DLTs for the first cycle, by study dosing schedule, initial dosing level and overall for the dose escalation part. The RP2D of golvatinib in Combination with lenvatinib was MTD determined by Dose Escalation Committee (DEC) based on safety, PK and clinical data. DLT was defined as toxicity related to the combination therapy and was graded according to CTCAE v4.0.
| milligram per day (mg/day) | All Cohorts: Golvatinib + Lenvatinib |
|---|---|
| MTD | 300.0 |
| RP2D | 300.0 |
The MTD was defined as the highest dose level at which no more than 1/6 participants experienced a DLTs, with the next higher dose having at least 0 of 3 or 1 of 6 participants experiencing DLTs. MTD was determined by summarizing the number and percentage of participants with DLTs for the first cycle, by study dosing schedule, initial dosing level and overall for the dose escalation part. The RP2D of lenvatinib in Combination with golvatinib was MTD determined by DEC based on safety, PK and clinical data. DLT was defined as toxicity related to the combination therapy and was graded according to CTCAE v4.0.
| mg/day | All Cohorts: Lenvatinib + Golvatinib |
|---|---|
| MTD | 20.0 |
| RP2D | 20.0 |
| Participants | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Phase 1b: Number of Participants With Clinically Significant Change From Baseline in Laboratory Values- Combination Treatment | 0 | 0 | 0 | 0 |
| Participants | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Phase 1b: Number of Participants With Clinically Significant Change From Baseline in Vital Signs Values- Combination Treatment | 0 | 0 | 0 | 0 |
| Participants | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Baseline and post-baseline data | 3 | 3 | 13 | 8 |
| At least 1 post-baseline increase of greater than (>) 30 millisecond (msec) | 2 | 0 | 1 | 4 |
| At least 1 post-baseline increase of > 60 msec | 1 | 0 | 0 | 0 |
| At least 1 post-baseline value of > 450 msec | 2 | 2 | 8 | 4 |
| At least 1 post-baseline value of > 480 msec | 1 | 0 | 4 | 1 |
| At least 1 post-baseline value of > 500 msec | 1 | 0 | 1 | 0 |
| Participants | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| TEAEs | 3 | 3 | 14 | 8 |
| SAEs | 2 | 1 | 8 | 3 |
| nanograms per milliliter (ng/mL) | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Phase 1b: Cmax; Maximum Observed Plasma Concentration for Golvatinib When Administered as a Single Agent at Day -7 | 2160 ± 848 | 1710 ± 1410 | 3020 ± 2130 | 3930 ± 1800 |
| ng/mL | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Phase 1b: Cmax; Maximum Observed Plasma Concentration for Lenvatinib When Administered as a Single Agent at Day -8 | 174 ± 88.0 | 393 ± 75.0 | 297 ± 159 | 388 ± 250 |
| hours | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Phase 1b: Tmax; Time to Reach the Maximum Plasma Concentration (Cmax) for Golvatinib When Administered as a Single Agent at Day -7 | 2.00 (1.43 to 11.6) | 4.00 (3.02 to 4.08) | 2.54 (1.95 to 4.08) | 2.54 (1.98 to 7.92) |
| hours | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Phase 1b: Tmax; Time to Reach the Maximum Plasma Concentration (Cmax) for Lenvatinib When Administered as a Single Agent at Day -8 | 3.00 (1.00 to 3.08) | 2.00 (2.00 to 2.92) | 3.01 (1.93 to 8.00) | 3.00 (1.00 to 23.50) |
| nanogram*hour per milliliter(ng*h/mL) | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Phase 1b: AUC24; Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for Golvatinib When Administered as Single Agent at Day -7 | 25600 ± 6720 | 19300 ± 14000 | 34400 ± 25600 | 50000 ± 27900 |
| ng*h/mL | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Phase 1b: AUC24; Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for Lenvatinib When Administered as Single Agent at Day -8 | 1540 ± 581 | 2690 ± 75.7 | 2620 ± 1160 | 3200 ± 2210 |
| ng*h/mL | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Phase 1b: AUCt; Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for Golvatinib When Administered as Single Agent at Day -7 | 26500 ± 6380 | 34700 ± 27900 | 38000 ± 25400 | 64000 ± 33000 |
| ng*h/mL | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Phase 1b: AUCt; Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for Lenvatinib When Administered as Single Agent at Day -8 | 1800 ± 697 | 3030 ± 254 | 3030 ± 1260 | 3780 ± 2630 |
| ng*h/mL | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Phase 1b: AUC∞; Area Under the Plasma Concentration-time Curve From Time 0 to Infinity Calculated Using the Observed Value for the Last Quantifiable Concentration for Golvatinib When Administered as Single Agent at Day -7 | — | 58300 ± 23500 | 51200 ± NA | — |
| ng*h/mL | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Phase 1b: AUC∞; Area Under the Plasma Concentration-time Curve From Time 0 to Infinity Calculated Using the Observed Value for the Last Quantifiable Concentration for Lenvatinib When Administered as Single Agent at Day -8 | 1890 ± 693 | 3060 ± 250 | 2930 ± 1360 | 3910 ± 2680 |
| hours | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Phase 1b: t1/2; Terminal Elimination Half-life for Golvatinib When Administered as Single Agent at Day -7 | — | 34.6 ± 1.77 | 30.7 ± NA | 57.0 ± 1.70 |
| hours | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Phase 1b: t1/2; Terminal Elimination Half-life for Lenvatinib When Administered as Single Agent at Day -8 | 11.2 ± 3.27 | 14.6 ± 6.69 | 12.0 ± 5.49 | 14.4 ± 6.86 |
| liter per hour (L/h) | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Phase 1b: CL/F; Apparent Clearance After Extravascular Administration Calculated Using the Observed Value of the Last Quantifiable Concentration for Golvatinib When Administered as Single Agent at Day -7 | — | 3.74 ± 1.51 | 5.87 ± NA | — |
| liter per hour (L/h) | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Phase 1b: CL/F; Apparent Clearance After Extravascular Administration Calculated Using the Observed Value of the Last Quantifiable Concentration for Lenvatinib When Administered as Single Agent at Day -8 | 7.01 ± 2.31 | 6.57 ± 0.556 | 8.63 ± 5.33 | 7.23 ± 4.25 |
| liter (L) | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Phase 1b: Vz/F; Apparent Volume of Distribution at Terminal Phase for Golvatinib When Administered as Single Agent at Day -7 | — | 188 ± 84.9 | 260 ± NA | — |
| liter (L) | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Phase 1b: Vz/F; Apparent Volume of Distribution at Terminal Phase for Lenvatinib When Administered as Single Agent at Day -8 | 112 ± 53.4 | 135 ± 55.1 | 182 ± 209 | 137 ± 87.5 |
| ng/mL | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Golvatinib: Cycle 1 Day 1 | 2890 ± 1080 | 1990 ± 1470 | 3050 ± 1030 | 4820 ± 1510 |
| Lenvatinib: Cycle 1 Day 1 | 182 ± 137 | 315 ± 35.4 | 258 ± 148 | 251 ± 144 |
| ng/mL | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Golvatinib: Cycle 2 Day 1 | 3540 ± NA | 2750 ± 870 | 3570 ± 1350 | 6920 ± 4130 |
| Lenvatinib: Cycle 2 Day 1 | 66.3 ± NA | 356 ± 76.4 | 245 ± 110 | 408 ± 250 |
| hours | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Golvatinib: Cycle 1 Day 1 | 3.02 (2.12 to 4.02) | 4.00 (2.03 to 4.08) | 3.52 (1.98 to 8.05) | 3.00 (0.98 to 4.13) |
| Lenvatinib: Cycle 1 Day 1 | 3.02 (2.12 to 4.02) | 2.02 (2.00 to 2.03) | 3.95 (1.98 to 4.03) | 3.98 (2.00 to 4.13) |
| hours | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Golvatinib: Cycle 2 Day 1 | 8.05 (8.05 to 8.05) | 2.00 (1.00 to 3.00) | 2.97 (1.02 to 3.97) | 3.53 (3.00 to 7.92) |
| Lenvatinib: Cycle 2 Day 1 | 10.55 (10.55 to 10.55) | 3.00 (2.00 to 4.00) | 3.90 (2.03 to 3.97) | 3.53 (2.00 to 7.92) |
| ng*h/mL | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Golvatinib: Cycle 1 Day 1 | 33800 ± 4270 | 22100 ± 15900 | 38700 ± 21700 | 60400 ± 26200 |
| Lenvatinib: Cycle 1 Day 1 | 1460 ± 922 | 2370 ± 35.4 | 2290 ± 1250 | 2390 ± 1710 |
| ng*h/mL | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Golvatinib: Cycle 2 Day 1 | 68700 ± NA | 45000 ± 29700 | 57100 ± 25300 | 138000 ± 98900 |
| Lenvatinib: Cycle 2 Day 1 | 1120 ± NA | 3060 ± 247 | 2380 ± 1430 | 4320 ± 3860 |
| ng*h/mL | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Golvatinib: Cycle 1 Day 1 | 34000 ± 4290 | 22200 ± 15900 | 39800 ± 21800 | 60800 ± 26700 |
| Lenvatinib: Cycle 1 Day 1 | 1470 ± 921 | 2370 ± 42.4 | 2400 ± 1270 | 2400 ± 1730 |
| ng*h/mL | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Golvatinib: Cycle 2 Day 1 | 68700 ± NA | 45200 ± 29500 | 57100 ± 25300 | 138000 ± 98700 |
| Lenvatinib: Cycle 2 Day 1 | 1120 ± NA | 3060 ± 255 | 2380 ± 1430 | 4330 ± 3850 |
| liter per hour (L/h) | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Golvatinib: Cycle 2 Day 1 | — | 5.69 ± 3.76 | — | 3.49 ± 1.81 |
| Lenvatinib: Cycle 2 Day 1 | — | 6.58 ± 0.54 | — | 7.96 ± 5.72 |
| ratio | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Golvatinib: Cycle 2 Day 1 | 2.35 ± NA | 3.96 ± 2.14 | 1.90 ± 0.905 | 2.10 ± 0.254 |
| Lenvatinib: Cycle 2 Day 1 | 1.88 ± NA | 1.29 ± 0.127 | 0.928 ± 0.295 | 1.61 ± 0.670 |
| ratio | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Golvatinib: Cycle 2 Day 1 | 2.11 ± NA | 3.16 ± 2.24 | 1.30 ± 0.481 | 1.49 ± 0.319 |
| Lenvatinib: Cycle 2 Day 1 | 1.44 ± NA | 1.13 ± 0.120 | 1.17 ± 0.556 | 1.63 ± 1.27 |
ORR was assessed by the investigator based on Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. ORR was defined as the percentage of participants with confirmed best overall response (BOR) of complete response (CR) or partial response (PR). CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (\<)10 millimeters (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| Phase 1b: Objective Response Rate (ORR); Combination Treatment | 0 (NA to NA) | 0 (NA to NA) | 28.6 (8.4 to 58.1) | 12.5 (0.3 to 52.7) |
Collected over From baseline up to approximately 5 years 5 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | 1/3 (33.3%) | 2/3 (66.7%) | 3/3 (100%) |
| Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | 0/14 (0%) | 8/14 (57.1%) | 13/14 (92.9%) |
| Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg | 3/8 (37.5%) | 3/8 (37.5%) | 8/8 (100%) |
| Event | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| PyrexiaGeneral disorders | 1/3 | 0/3 | 0/14 | 0/8 |
| Lung InfectionInfections and infestations | 0/3 | 1/3 | 0/14 | 0/8 |
| Back PainMusculoskeletal and connective tissue disorders | 1/3 | 0/3 | 1/14 | 0/8 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 1/3 | 0/3 | 0/14 | 1/8 |
| Electrocardiogram Qt ProlongedInvestigations | 1/3 | 0/3 | 0/14 | 0/8 |
| Malignant Pleural EffusionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/3 | 0/3 | 0/14 | 0/8 |
| Abdominal PainGastrointestinal disorders | 0/3 | 0/3 | 2/14 | 0/8 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 0/3 | 0/14 | 1/8 |
| BacteraemiaInfections and infestations | 0/3 | 0/3 | 0/14 | 1/8 |
| Musculoskeletal Chest PainMusculoskeletal and connective tissue disorders | 0/3 | 0/3 | 0/14 | 1/8 |
| Event | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg |
|---|---|---|---|---|
| VomitingGastrointestinal disorders | 3/3 | 2/3 | 9/14 | 6/8 |
| FatigueGeneral disorders | 2/3 | 3/3 | 11/14 | 5/8 |
| Decreased AppetiteMetabolism and nutrition disorders | 3/3 | 2/3 | 10/14 | 5/8 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 1/3 | 3/3 | 3/14 | 3/8 |
| NauseaGastrointestinal disorders | 3/3 | 3/3 | 7/14 | 4/8 |
| DiarrhoeaGastrointestinal disorders | 1/3 | 2/3 | 13/14 | 5/8 |
| Aspartate Aminotransferase IncreasedInvestigations | 1/3 | 0/3 | 10/14 | 3/8 |
| Oral PainGastrointestinal disorders | 0/3 | 2/3 | 2/14 | 0/8 |
| AstheniaGeneral disorders | 2/3 | 0/3 | 1/14 | 1/8 |
| DehydrationMetabolism and nutrition disorders | 2/3 | 0/3 | 7/14 | 4/8 |
The safety analysis set (combination treatment) included all participants who received at least 1 dose of combination treatment and had at least 1 postbaseline safety evaluation.
| Age, Continuous(years) | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg | Total |
|---|---|---|---|---|---|
| Median | 58.0 (36 to 66) | 63.0 (54 to 65) | 64.5 (41 to 75) | 56.5 (34 to 73) | 62.0 (34 to 75) |
| Sex: Female, Male(Participants) | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg | Total |
|---|---|---|---|---|---|
| Female | 1 | 1 | 7 | 4 | 13 |
| Male | 2 | 2 | 7 | 4 | 15 |
| Race/Ethnicity, Customized(Participants) | Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg | Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg | Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg | Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg | Total |
|---|---|---|---|---|---|
| White | 3 | 3 | 12 | 8 | 26 |
| Asian | 0 | 0 | 1 | 0 | 1 |
| Other | 0 | 0 | 1 | 0 | 1 |
Ran from Oct 2011 to primary completion in Mar 2015, 41 months.
Results were first posted in Jun 2021, 6 years 2 months after primary completion. A results delay was requested in Apr 2016.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Golvatinib · Lenvatinib